GlassScriptPhysician profile
Amy Trinh
NPI 1659869378
$18,964.90
in general payments reported to CMS, 2019-2025
36 companies · $4,070 in 2025
The $4,070 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $137 · 2021: $1,297 · 2022: $4,782 · 2023: $4,274 · 2024: $4,300 · 2025: $4,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,181.51 |
| Education | $462.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,790.45 | 2021-2025 | Tavneos, Evenity, Otezla |
| Janssen Biotech, INC. | $3,207.73 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $2,575.56 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $1,510.65 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $1,505.93 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,136.23 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $850.92 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $569.72 | 2023-2025 | Orencia |
| Janssen Scientific Affairs, LLC | $444.17 | 2022-2025 | Tremfya |
| Pfizer INC. | $406.30 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.67 | 2021-2025 | Ofev, Cyltezo, Spevigo |
| United Therapeutics Corporation | $369.26 | 2023-2025 | Tyvaso |
| Horizon Therapeutics Plc | $321.10 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $305.56 | 2021-2024 | Acthar |
| Radius Health, INC. | $216.13 | 2023-2025 | Tymlos |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $209.62 | 2022-2025 | Strensiq, Ultomiris |
| Lilly USA, LLC | $207.20 | 2019-2025 | Taltz, Zepbound |
| Actelion Pharmaceuticals US, INC. | $139.56 | 2022-2023 | Uptravi, Opsumit |
| Genzyme Corporation | $132.93 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $107.53 | 2023-2025 | Idacio |
| Glaxosmithkline, LLC. | $106.56 | 2019-2023 | Benlysta |
| Alvogen INC | $77.83 | 2022-2025 | Teriparatide |
| Organon LLC | $61.02 | 2024-2025 | Hadlima |
| Aurinia Pharma U.S., INC. | $53.62 | 2022-2023 | Lupkynis |
| Sandoz INC. | $49.38 | 2023-2024 | Hyrimoz |
| Sobi, INC | $36.69 | 2023 | |
| Bioventus LLC | $23.32 | 2025 | Gelsyn-3 |
| Invivyd INC | $22.92 | 2025 | Pemgarda |
| Kiniksa Pharmaceuticals International, Plc | $20.74 | 2024 | Arcalyst |
| Mylan Institutional INC. | $19.81 | 2023 | |
| Fidia Pharma USA INC. | $18.72 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $18.34 | 2020 | |
| Kyowa Kirin, INC. | $17.08 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.51 | 2025 | Voquezna |
| Myovant Sciences INC. | $13.14 | 2021 | |
| Merck Sharp & Dohme LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Trinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.